Flow Electroporation for Stable Cell Line Generation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for generating stable cell lines for recombinant protein production face challenges such as low transfection efficiency and high cell viability issues, leading to resource-intensive and time-consuming selection processes.

Innovation Solution

The use of flow electroporation to transfect cells with an expression construct containing a selectable gene and a sequence encoding an exogenous polypeptide, followed by selection under conditionally lethal concentrations of a selection agent to produce high-producing stable cell lines.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional transfection methods (PEI, lipid methods) are used, then the process is simple to operate, but transfection efficiency is low

Engineering Contradiction:
Improvetransfection efficiencyVSAvoidease of operation
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

The patent replaces conventional chemical transfection methods (PEI, lipid-based) with flow electroporation, which uses controlled electrical fields to facilitate DNA entry into cells. This mechanical/physical approach achieves superior transfection efficiency (≥70%) compared to chemical methods while maintaining operational simplicity through automated flow-based processing.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent employs flow electroporation with optimized electrical parameters (voltage, pulse duration, flow rate) to achieve high transfection efficiency. By precisely controlling the electrical field parameters and cell flow conditions, the method overcomes the limitations of conventional chemical transfection methods.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If conventional transfection methods are used, then the procedure is less complex, but cell viability is reduced

Engineering Contradiction:
Improvecell viabilityVSAvoiddevice complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent replaces harsh chemical transfection reagents with a controlled electrical field approach in flow electroporation. This mechanical substitution achieves ≥70% cell viability post-transfection, significantly improving upon the cell death caused by chemical methods while using a sophisticated but controlled device system.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The flow electroporation system applies periodic electrical pulses to cells as they flow through the treatment zone. This pulsed electrical action allows for controlled membrane permeabilization and recovery, maintaining high cell viability while achieving effective transfection.

Inventive Principle:
Principle #19Periodic action

3Reliability

If several thousand clones are screened to identify good stable clones, then the selection is thorough, but the process becomes time-consuming and resource-intensive

Engineering Contradiction:
Improveselection accuracyVSAvoiddevelopment time
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent uses a conditionally lethal concentration of selection agent during the selection phase to pre-filter and enrich for high-expressing clones before final screening. This preliminary selective action reduces the number of clones that need to be fully characterized, thereby maintaining selection accuracy while reducing overall development time and resource requirements.

Inventive Principle:
Principle #10Preliminary action

4Productivity

If high concentration of selection agent is used to rapidly select stable clones, then the selection speed increases, but untransfected cells are killed along with low-expressing transfected cells

Engineering Contradiction:
Improveselection speedVSAvoidclone quality
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent employs a conditionally lethal concentration of selection agent that is optimized to kill untransfected cells while preserving both low-expressing and high-expressing transfected clones. This precise parameter control enables rapid selection without sacrificing clone quality, as the selection pressure is calibrated to distinguish between transfected and untransfected cells specifically.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method achieves high transfection efficiency and cell viability, significantly reducing the time and resources required to identify stable cell lines, enabling rapid generation of high-yield cell lines for protein production.

Implementation Method 1

transfecting a composition comprising nucleic acid into a cell by exposing the cell to an electric field in a flow state such that the cell takes up the nucleic acid

Methodology Applied
Scientific EffectElectroporation:

Data Source

PatentEP2970915B1Methods and compositions for generating stable transfected cells
Publication Date: 2019.08.14 MAXCYTE INC
  • EP2970915B1 patent drawingFigure 1
  • EP2970915B1 patent drawingFigure 2
  • EP2970915B1 patent drawingFigure 3

AI summary

Methods and compositions are provided involving high producing cell lines. Embodiments concern efficient methods for screening for such cell lines and for creating such cell lines. These cell lines can be used to create large amounts of protein. To quickly generate large quantity of recombinant proteins or vaccines for both pre-clinical study and clinical trials, almost all drug development will face the same challenging obstacle of rapidly generating a high stable producer. Developing and identifying a stable cell line is a critical part of biopharmaceutical development.